Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8528677 | 0.83 | L3MBTL1 (0.35) | HRH2HRH1HRH4HRH3TDP1 | |
| SCHEMBL11329931 | 0.81 | GABRR1 (0.36) | HRH2HRH1HRH4HRH3TDP1 | |
| SCHEMBL11319237 | 0.81 | HRH2 (0.34) | HRH2HRH1HRH4HRH3TDP1 | |
| SCHEMBL11530311 | 0.79 | — | — | |
| SCHEMBL8528671 | 0.76 | L3MBTL1 (0.33) | HRH2HRH1HRH4HRH3TDP1 | |
| SCHEMBL23393724 | 0.71 | HRH2 (0.33) | HRH2HRH1HRH4HRH3TDP1 | |
| SCHEMBL27785542 | 0.70 | — | — | |
| SCHEMBL9967679 | 0.70 | — | — | |
| SCHEMBL4546365 | 0.70 | — | — | |
| SCHEMBL7857005 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024126777-A1 | HETEROAROMATIC COMPOUNDS | ASTRAZENECA AB (SE) | 2024-06-20 | — | — | WO | disclosed |
| US-20230174565-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230023761-A1 | SUBSTITUTED PYRIDINES AS TYK2 INHIBITORS | ALUMIS INC. | 2023-01-26 | — | — | US | disclosed |
| US-20220169634-A1 | AROMATIC DERIVATIVES, PREPARATION METHODS, AND MEDICAL USES THEREOF | BIOARDIS LLC | 2022-06-02 | — | — | US | disclosed |
| US-11345716-B2 | Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect | SHIONOGI & CO., LTD. (JP) | 2022-05-31 | — | — | US | disclosed |
| WO-2021113849-A1 | HER2+ CANCER TREATMENT WITH POPULATIONS OF NATURAL KILLER CELLS COMPRISING A CLEAVAGE RESISTANT CD16 | CELULARITY INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| US-20210009607-A1 | NITROGEN-CONTAINING CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 ANTAGONISTIC EFFECT | SHIONOGI & CO., LTD. (JP) | 2021-01-14 | — | — | US | disclosed |
| US-10870660-B2 | Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect | SHIONOGI & CO., LTD. (JP) | 2020-12-22 | — | — | US | disclosed |
| US-20190161501-A1 | NITROGEN-CONTAINING CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 ANTAGONISTIC EFFECT | SHIONOGI & CO., LTD. (JP) | 2019-05-30 | — | — | US | disclosed |
| US-9598411-B2 | Substituted benzimidazole-type piperidine compounds and uses thereof | PURDUE PHARMA L.P. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20120157461-A1 | Indolyl-Substituted Pyrazino-Quinolines and Their Use for the Treatment of Cancer | ONKILL AB (SE) | 2012-06-21 | — | — | US | disclosed |
| WO-2008136815-A2 | 5, 6-RING ANNULATED INDOLE DERIVATIVES AND USE THEREOF | SCHERING CORPORATION (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345716-B2 | Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect | DRD3, DRD4, DRD2 | HRH2 301/4885HRH1 388/4885HRH4 46/4885 |
| US-10870660-B2 | Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect | DRD3, DRD4, DRD2 | HRH2 301/4885HRH1 388/4885HRH4 46/4885 |
| US-20230023761-A1 | SUBSTITUTED PYRIDINES AS TYK2 INHIBITORS | TYK2, JAK1, PDXK | HRH2 2457/4885HRH1 1976/4885HRH4 1678/4885 |
| US-20220169634-A1 | AROMATIC DERIVATIVES, PREPARATION METHODS, AND MEDICAL USES THEREOF | FGFR4, FGFR3, FGFR1 | HRH2 601/4885HRH1 684/4885HRH4 139/4885 |
| US-20210009607-A1 | NITROGEN-CONTAINING CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 ANTAGONISTIC EFFECT | DRD3, DRD4, DRD2 | HRH2 301/4885HRH1 388/4885HRH4 46/4885 |
| US-20120157461-A1 | Indolyl-Substituted Pyrazino-Quinolines and Their Use for the Treatment of Cancer | TPD52L2, FLT4, FLT1 | HRH2 748/4885HRH1 798/4885HRH4 305/4885 |
| US-20190161501-A1 | NITROGEN-CONTAINING CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 ANTAGONISTIC EFFECT | DRD3, DRD4, DRD2 | HRH2 301/4885HRH1 388/4885HRH4 46/4885 |
| US-20230174565-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | HRH2 427/4885HRH1 508/4885HRH4 849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.